Cargando…

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with ((123)I) ioflupane in diagnosis of parkinsonian syndromes

The diagnosis of movement disorders including Parkinson's disease (PD) and essential tremor is determined through clinical assessment. The difficulty with diagnosis of early PD has been highlighted in several recent clinical trials. Studies have suggested relatively high clinical diagnostic err...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bajaj, Nin, Hauser, Robert A, Grachev, Igor D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Movement Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812862/ https://www.ncbi.nlm.nih.gov/pubmed/23486993 http://dx.doi.org/10.1136/jnnp-2012-304436

Ejemplares similares

Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes
por: Bajaj, Nin, et al.
Publicado: (2014)

The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders
por: Rittman, Timothy, et al.
Publicado: (2013)

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes
por: Jabbari, Edwin, et al.
Publicado: (2019)

(123)I-ioflupane brain SPECT and (123)I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders
por: Nuvoli, Susanna, et al.
Publicado: (2017)

Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of (123)I-Ioflupane SPECT: an investigation of parkinsonian syndromes
por: Iwabuchi, Yu, et al.
Publicado: (2019)

Diagnostic Effectiveness of [(123)I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy
por: Villena-Salinas, Javier, et al.
Publicado: (2023)

Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study
por: Erro, Roberto, et al.
Publicado: (2021)

CT-Based Attenuation Correction in I-123-Ioflupane SPECT
por: Lange, Catharina, et al.
Publicado: (2014)

Magnetic resonance and dopamine transporter imaging for the diagnosis of Parkinson´s disease: a narrative review
por: Otani, Rafael Tomio Vicentini, et al.
Publicado: (2022)

Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study
por: Malek, Naveed, et al.
Publicado: (2018)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
por: Swallow, Diane M A, et al.
Publicado: (2016)

Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression
por: Lawton, Michael, et al.
Publicado: (2018)

The role of (123)I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies
por: Antonini, Angelo
Publicado: (2007)

Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study
por: Tsang, Kaki, et al.
Publicado: (2023)

Association between body mass index (BMI) and [(123)I]Ioflupane (DaTSCAN) availabilities in patients with parkinsonism using single-photon emission computed tomography–computed tomography (SPECT-CT)
por: Parekh, Puja, et al.
Publicado: (2023)

Follow-Up Findings in Multiple System Atrophy from [(123)I]Ioflupane Single-Photon Emission Computed Tomography (SPECT): A Prospective Study
por: Villena-Salinas, Javier, et al.
Publicado: (2023)

Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses
por: Badoud, Simon, et al.
Publicado: (2016)

Brain tissue echogenicity—implications for substantia nigra studies in parkinsonian patients
por: Sadowski, Krzysztof, et al.
Publicado: (2011)

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
por: Fernandez, Hubert H, et al.
Publicado: (2019)

Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging
por: Covington, Matthew F., et al.
Publicado: (2015)

Interpreting (123)I–ioflupane dopamine transporter scans using hybrid scores
por: Nichols, Kenneth J., et al.
Publicado: (2018)

Visual hallucinations in the differential diagnosis of parkinsonism
por: Bertram, Kelly, et al.
Publicado: (2012)

Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia
por: Becker, Esther B E, et al.
Publicado: (2012)

Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
por: Moreau, Caroline, et al.
Publicado: (2013)

The differential diagnosis of Huntington's disease-like syndromes: ‘red flags’ for the clinician
por: Martino, Davide, et al.
Publicado: (2013)

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease
por: Barker, Roger A, et al.
Publicado: (2013)

The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism
por: Klebe, Stephan, et al.
Publicado: (2013)

Bone health in Parkinson's disease: a systematic review and meta-analysis
por: Torsney, Kelli M, et al.
Publicado: (2014)

Fetal striatal grafting slows motor and cognitive decline of Huntington's disease
por: Paganini, Marco, et al.
Publicado: (2014)

Rest and other types of tremor in adult-onset primary dystonia
por: Erro, Roberto, et al.
Publicado: (2014)

Cortical thinning is associated with disease stages and dementia in Parkinson's disease
por: Zarei, Mojtaba, et al.
Publicado: (2013)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Pisa syndrome in Parkinson's disease: a mobile or fixed deformity?
por: Doherty, Karen M, et al.
Publicado: (2013)

PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results
por: Noyce, Alastair J, et al.
Publicado: (2014)

REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease
por: Rolinski, Michal, et al.
Publicado: (2014)

Effect of subthalamic nucleus deep brain stimulation on dual-task cognitive and motor performance in isolated dystonia
por: Mills, Kelly A, et al.
Publicado: (2015)

Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach
por: Aviles-Olmos, Iciar, et al.
Publicado: (2014)

Using ‘dead or dependent’ as an outcome measure in clinical trials in Parkinson's disease
por: McGhee, David, et al.
Publicado: (2015)

Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency
por: Mochel, Fanny, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gnp9tms3jupgqmgdtann4hidci